Intracellular ROS
Overview
Intracellular ROS refers to reactive oxygen species generated within cells, including species such as superoxide, hydrogen peroxide, and related oxidants that participate in redox signaling but can also drive oxidative damage when produced in excess. In normal physiology, intracellular ROS help regulate processes such as proliferation, differentiation, immune signaling, and stress responses. Their levels are tightly controlled by antioxidant systems including glutathione, Superoxide Dismutase (SOD), Catalase (CAT), and glutathione peroxidase.
In biomedical research, intracellular ROS is commonly treated as a mechanistic readout and therapeutic target because many diseases involve redox imbalance. Elevated intracellular ROS is associated with apoptosis, ferroptosis, mitochondrial dysfunction, DNA damage, inflammation, cellular senescence, and tissue injury, while ROS scavenging or suppression is often linked to cytoprotection and restoration of redox homeostasis. Conversely, many anticancer and antimicrobial strategies intentionally increase intracellular ROS to overwhelm tumor or pathogen defenses, often in combination with photochemotherapy, cuproptosis, ferroptosis, or chemotherapy.
Recent Publications Summary
Recent studies have examined intracellular ROS as a central mediator of therapeutic response, particularly in cancer and inflammatory disease models. In oral cancer cells, santamarine combined with cisplatin increased cellular and mitochondrial ROS, which was associated with apoptosis, caspase-3/-8/-9 activation, DNA damage markers, and cell-cycle arrest; JNK inhibition reversed these effects, supporting a ROS/JNK-dependent mechanism 42187533May. A separate ROS-responsive prodrug nanoparticle system co-delivering curcumin and (E)-cinnamaldehyde was designed to disrupt tumor redox homeostasis in 4T1 tumor cells by intracellular release of pro-oxidant cargo, highlighting ROS-targeted redox imbalance as a therapeutic strategy 42090188May.
Other publications focused on ROS scavenging to reduce oxidative injury and reshape the inflammatory microenvironment. A cerium-doped carbon quantum dot platform was developed to penetrate the blood–brain barrier and eliminate excess ROS in LPS-induced encephalitis, while also targeting M1 macrophages and modulating macrophage polarization to alleviate neuroinflammation 42138488May. Similarly, antioxidative lignin@Fe3O4 nanoclusters on a magneto-actuated scaffold scavenged ROS while delivering mechanical stimulation, promoting macrophage transition from M1 to M2 and improving tissue integration after implantation 42138137May. In diabetic wound repair, a ROS-responsive hyaluronic acid-based hydrogel carrying tannic acid-complexed siRNA nanogels reduced oxidative stress, promoted M2 repolarization, enhanced endothelial migration and tubulogenesis, and accelerated wound closure 42067084May.
ROS generation was also leveraged for antimicrobial and imaging applications. Visible-light-driven cysteine-derived carbon dots produced ROS under illumination to achieve potent antibacterial activity against Staphylococcus aureus and Escherichia coli, with oxidative damage proposed as the basis for resistance-sparing sterilization in infected wound healing 42113536May. In a separate bioimaging approach, chromophores with high ROS generation capability were encapsulated in PMMA nanospheres to create an aqueous room-temperature phosphorescence probe, where endogenous oxygen depletion and ROS production helped suppress quenching by water and oxygen 42097976May. Finally, one analytical study reported that high-concentration TCEP injections could remove unwanted ROS from LC systems and prevent artificial methionine oxidation during monoclonal antibody peptide mapping, underscoring the relevance of ROS control even in bioanalytical workflows 42034288Apr.
What Changes, What Holds
1. ROS-linked pro-oxidant combinations strengthen the case for deliberately pushing intracellular redox stress in cancer therapy
REINFORCES Santamarine plus cisplatin and the ROS-responsive nanoparticle both fit the established view that intracellular ROS can be therapeutically exploited to trigger apoptosis and redox collapse in cancer cells. What these studies add is not a new role for ROS, but a more explicit mechanistic framing around ROS/JNK signaling and intracellular release of pro-oxidant cargo as ways to intensify an already recognized anticancer strategy 42187533May42090188May.
2. ROS scavenging is being extended from cytoprotection to microenvironment remodeling
NEW DIRECTION These studies do not challenge the baseline claim that ROS suppression can be protective; they broaden it by showing that lowering intracellular ROS can also reshape inflammatory and repair niches through macrophage polarization and barrier-penetrant delivery. That moves ROS control from a simple antioxidant readout toward an intervention that can coordinate tissue repair, neuroinflammation, and wound healing, while leaving the core redox-homeostasis account intact 42138488May42138137May.
3. ROS generation is being repurposed for antimicrobial action and assay control
NEW DIRECTION Visible-light ROS production for antibacterial sterilization extends the established damage model into infection control, but the bioimaging and LC workflow findings sit outside the Overview’s therapeutic framing altogether. They show that intracellular or system-adjacent ROS management now matters in imaging probe design and analytical artifact prevention as well, so the baseline’s disease-centered account is incomplete rather than contradicted 42113536May42034288Apr.
Overview update candidates: ROS scavenging as a means to modulate macrophage polarization and tissue repair; ROS generation as a resistance-sparing antibacterial strategy.
intracellular ros
Background Contexts
In the literature, the biological baseline, pathological conditions, or disease models commonly surrounding intracellular ros are described as follows:
- triple-negative (Other) — 4 papers: PMIDs 42174637, 42114042, 41881862, 41812835
- blood–brain barrier (Biological Process) — 2 papers: PMIDs 42138488, 42044766
- cognitive diseases (Disease) — 2 papers: PMIDs 42185568, 42171824
- diabetes status (Disease) — 2 papers: PMIDs 42101831, 42025374
- diabetic nephropathy (Disease) — 2 papers: PMIDs 42223693, 42159303
- ferroptosis (Biological Process) — 2 papers: PMIDs 42192119, 42053244
- GSH levels (Chemical) — 2 papers: PMIDs 42192119, 42002062
- acute and subacute ischemic stroke (Disease) — 1 paper: PMIDs 42044766
- Advanced Colorectal Cancer (Disease) — 1 paper: PMIDs 42204072
- anthracycline polyketide (Therapy) — 1 paper: PMIDs 41905253
- atheroma (Other) — 1 paper: PMIDs 42117484
- biofilm recalcitrance (Disease) — 1 paper: PMIDs 42113536
Methodologies & Technologies Used
Researchers utilize the following experimental methods, imaging platforms, computational models, or biological reagents to study intracellular ros:
- 4T1 models (Cell Line) — 2 papers: PMIDs 42174637, 42153635
- Caenorhabditis elegans (Organism) — 2 papers: PMIDs 42159234, 42105691
- Fenton-like reaction (Biological Process) — 2 papers: PMIDs 42097419, 42002062
- Glutathione peroxidase (Clinical Metric) — 2 papers: PMIDs 42159303, 42043281
- GSH levels (Chemical) — 2 papers: PMIDs 42183937, 42097419
- HCT116 colon cell line (Cell Line) — 2 papers: PMIDs 42204072, 42171754
- high glucose (Other) — 2 papers: PMIDs 42223693, 42159303
- HT-29 (Cell Line) — 2 papers: PMIDs 42204072, 42171754
- Hyaluronan sodium (Chemical) — 2 papers: PMIDs 42067084, 41943370
- MDA-MB-231 (Cell Line) — 2 papers: PMIDs 42153635, 41881862
- neoadjuvant or adjuvant chemotherapy (Biological Process) — 2 papers: PMIDs 42187533, 42070819
- photochemotherapy (Biological Process) — 2 papers: PMIDs 42126938, 42002062
Molecular Interventions & Targets
The primary molecular pathways, regulatory genes, enzymes, or therapeutic agents actively targeted and manipulated in relation to intracellular ros include:
- doxorubicin (Therapy) — 3 papers: PMIDs 42192119, 42043281, 41905253
- copper(2+) (Chemical) — 2 papers: PMIDs 42126988, 42002062
- growth factors TGF-β1 and VEGF (Protein) — 2 papers: PMIDs 42159303, 41943370
- nuclear factor kappa B (Protein) — 2 papers: PMIDs 42106045, 42102478
- pirfenidone (Therapy) — 2 papers: PMIDs 42159303, 41943370
- proinflammatory cytokine (Biological Process) — 2 papers: PMIDs 42102478, 41765235
- TP53 (Gene) — 2 papers: PMIDs 42163716, 41905253
- (E)-cinnamaldehyde (Chemical) — 1 paper: PMIDs 42090188
- 2-aminobenzonitriles (Chemical) — 1 paper: PMIDs 41881862
- 2-aminomethyl analog 2j (Chemical) — 1 paper: PMIDs 41905253
- 2-phenyl derivative 2b (Chemical) — 1 paper: PMIDs 41905253
- 2-substituted 4,11-diaminoanthra[2,3-b]furan-5,10-diones (Chemical) — 1 paper: PMIDs 41905253
Observed Outcomes & Phenotypes
The phenotypic changes, physiological endpoints, or clinical metrics observed and measured in connection with intracellular ros include:
- proinflammatory cytokine (Biological Process) — 9 papers: PMIDs 42223693, 42138395, 42105691, 42067091, etc.
- tumor cell apoptosis (Biological Process) — 7 papers: PMIDs 42174637, 42171754, 42153635, 42151142, etc.
- immunogenic cell death (Biological Process) — 4 papers: PMIDs 42174637, 42114042, 42093524, 42002062
- mitochondrial dysfunction (Biological Process) — 4 papers: PMIDs 42185568, 42159303, 42126988, 42002062
- mitochondrial membrane potential (Biological Process) — 4 papers: PMIDs 42185568, 42153635, 42090188, 41812835
- •OH radicals (Chemical) — 4 papers: PMIDs 42126988, 42097419, 42043281, 42002062
- adenosine triphosphate (Chemical) — 3 papers: PMIDs 42171824, 42093524, 42025984
- antitumor efficacy (Clinical Metric) — 3 papers: PMIDs 42138395, 42126988, 42097419
- biocompatibility (Other) — 3 papers: PMIDs 42106045, 42092663, 41943370
- collagen deposition (Clinical Metric) — 3 papers: PMIDs 42168679, 42067084, 41943357
- cuproptosis (Biological Process) — 3 papers: PMIDs 42126988, 42114042, 41990934
- ferroptosis (Biological Process) — 3 papers: PMIDs 42174637, 42114042, 42097419
General Takeaways & Clinical Potentials
The high-level concepts, clinical translations, and overarching conclusions proposed in the research surrounding intracellular ros are summarized below:
- therapeutic potential (Other) — 4 papers: PMIDs 42185568, 42171824, 42053244, 42025374
- ferroptosis (Biological Process) — 2 papers: PMIDs 42025374, 41812835
- inflammatory skin diseases (Disease) — 2 papers: PMIDs 42126938, 42106045
- 2-aminobenzonitriles (Chemical) — 1 paper: PMIDs 41881862
- 4,11-diaminoanthra[2,3-b]furan-5,10-dione scaffold (Chemical) — 1 paper: PMIDs 41905253
- Advanced Colorectal Cancer (Disease) — 1 paper: PMIDs 42093524
- Air Quality Control Strategies (Other) — 1 paper: PMIDs 42124380
- anti-PD-L1 checkpoint blockade (Therapy) — 1 paper: PMIDs 42114042
- anti-photoaging treatment (Therapy) — 1 paper: PMIDs 42102478
- antileishmanial strategy (Therapy) — 1 paper: PMIDs 41946389
- antineoplastic (Therapy) — 1 paper: PMIDs 41881862
- antioxidant metabolism (Biological Process) — 1 paper: PMIDs 42183937